{'fraction_non_alphanumeric': 0.023965141612200435, 'fraction_numerical': 0.0010893246187363835, 'mean_word_length': 5.708029197080292, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evaluation of the biocompatibility of novel peptide hydrogel in rabbit eye.

A peptide containing a RGD (arginine-glycine-aspartic acid) sequence as well as a hydrophobic N-fluorenyl-9-methoxycarbonyl (FMOC) tail was prepared via a standard FMOC solid-phase peptide synthesis technique. The supramolecular self-assembly of such peptide through pi-pi stacking from FMOC tail can transfer the peptide aqueous solution into a three-dimensional hydrogel. The biocompatibility of the peptide hydrogel was evaluated via clinical follow-up and histological analysis. The data obtained demonstrated that the peptide hydrogel exhibited good biocompatibility when injected to the subconjunctival space and anterior chamber of rabbit, indicating a potential application in ophthalmology as an implantable drug delivery system for the treatment to ocular anterior segment diseases such as glaucoma, iridocyclitis, and keratopathy.